Inflammatory Breast Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
Condition: Breast Cancer Interventions: Drug: Nivolumab 360 mg+ paclitaxel 80 mg/m2; Drug: Doxorubicin 60 mg/m2+Cyclophosphamide 600 mg/m2; Drug: Nivolumab 360 mg+ Docetaxel* 75 mg/m2 +Trastuzumab 8 mg/kg +Pertuzumab 840 mg; Drug: Doxorubicin 60 mg/m2 +Cyclophosphamide 600 mg/m2 Sponsor: New York University School of Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2018 Category: Research Source Type: clinical trials